O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.


2.487 visualizações

Publicada em

Current cardiac assessment cannot predict risk and does not take genetics into account e.g. ECG/Treadmill test. The gold standard angiogram is invasive. CADRA uses both genetic/non-genetic data to predict risk of heart disease over time. It is non-invasive and genetic data remains unchanged over time.

Publicada em: Saúde e medicina
  • Entre para ver os comentários


  1. 1. Predicting Coronary Artery Disease Risk with Genetic Information CADRA TEAM CADRA: Total number of interviews: 135 A/Prof Heng Chew Kiat (PI) Delicia Ooi (EL) Daniel Kirilly (EL) Henrik Glarbo (Mentor) Audrey Long (Mentor)
  2. 2. Background • CAD is leading cause of death in many parts of the world • No.2 killer in Singapore (One out of every 5 Singaporeans) • One third of heart attack without warning signs • Genetics can account up to 60% of heart disease CADRA
  3. 3. Problem:  Current cardiac assessment cannot predict risk and does not take genetics into account e.g. ECG/Treadmill test  Gold standard angiogram is invasive Solution:  CADRA uses both genetic/non-genetic data to predict risk of heart disease over time  Non-invasive and genetic data remains unchanged over time So what is the problem? CADRA
  4. 4.  Local cohort of 3000 healthy/CAD patients  National Science & Technology Board Grant  91% sensitivity, 76% specificity and overall accuracy of 83% Genotyping of 32 CAD susceptible genes Unique Prediction Algorithm Patient CADRA
  5. 5. Cost structure Revenue streams Key resources Key activities Key partners Value proposition Customer relationships Customer segments Channels • Hospitals • Clinics • Insurance companies • Gyms • Biotechnology companies • CAD risk prediction • Family members of CAD patients • High risk patients • Public • Biotechnology company • Direct sales of CADRA tests • License fees • Doctors • Marketing • Mass customized • Communities of interest • Genotyping • Updating database • Marketing • Genotyping • Database • Manpower • Reagents • Genotyping
  6. 6. Hypotheses WHO? Insights 15 Institutional doctors (NUHS, National Heart Centre, National Cancer Centre) • Prefer diagnostic tool rather than prediction tool • May have commercial value in private hospitals • 5 family members of CAD patients • 5 high risk patients • Interested in CADRA • Will take it under doctor’s recommendationHOW?
  7. 7. Value Key Partners Channels Customer Segments Cost Structure Key Activities Hypothesis CAD risk prediction Wellness clinics Wellness Physicians Health screenees Service Providers Regulatory compliance Experiment Genetic test Medical directors Clinical significance CADRA survey MDC/Axil Scientific HSA/MOH Lesson Learnt Add on to current screening Commercial value To advise lifestyle adjustments 90% willing to take up CADRA Reduce cost by 50% Class III medical device Valid/Invalid Valid Valid Valid Valid Valid Valid CADRA
  8. 8. Customer archetype 1-Doctor  Dr Crystal Ng  Medical Director of Parkway Shenton  80-120 patients daily (Asian patients)  Genetic testing is important  CADRA adds on to clinical diagnosis  Genetic testing for other diseases e.g. cancer  Launch CADRA across 6 clinics: Gleneagles Hospital Mount Elizabeth Hospital Parkway East Hospital Mount Elizabeth Novena Hospital Paragon The Arcade CADRA
  9. 9. Customer archetype 2-Health Screenee  Madam Yvonne Yap  44 years old, married with two kids  Goes for annual health screening check  Wants to know more about her own health  Add on to health package e.g. ECG/Treadmill test  Interested to take up CADRA  Lifestyle adjustments to improve health  Willing to pay 1000sgd for CADRA CADRA
  10. 10. Market size • Average cost US$22,000 per annum (AHA) • Average cost of US$16,000 per annum (MOH) Singapore Local: US$3billion Medical Tourism: US$1billion Research from 12 local wellness clinics o Average 9000patients per annum per clinic o Average foreigners (40%) o Average spending of US$800 per patient US$72 Million Asia Pacific US$90billion USA US$200billion CADRA
  11. 11. Business Model SPIN-OFF (CADRA) Genotyping laboratories Outsource Results Sales Report Health Screening Clinics NUS License  Generation of reports  Marketing/Business development  Medical workshops/seminars  Safety and regulations CADRA
  12. 12. Financial Projection (I) Start-up Expenses (Year 1) $ (SGD) License Fees 10,000 Company registration 5,000 Product development 20,000 Regulatory Compliance 50,000 Office Overhead 15,000 Manpower 120,000 Marketing 15,000 Other start-up expenses 25,000 Total 260,000 CADRA
  13. 13. Financial Projection (II) CADRA -1 0 1 2 3 4 5 6 7 8 9 Year 1 Year 2 Year 3 Year 4 SGDMillion -13% 20% 32% 52%
  14. 14. Progress Timeline Phase 1 (Sep’13-Feb’14) Phase 2 (Mar’14-Aug’14) Phase 3 (Sep’15-Feb’16) Phase 4 (Mar’16-Aug’16)  License  Company registration  POV grant  Partnerships  Kit development  HSA approval  MOH evaluation  HPB  Marketing  Medical Seminars  Asia Market  R&D CADRA
  15. 15. THANK YOU! Live your life L ve your heart TEAM CADRA